<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment selection for moderate to severe plaque psoriasis in special populations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment selection for moderate to severe plaque psoriasis in special populations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment selection for moderate to severe plaque psoriasis in special populations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April W Armstrong, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 01, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H9475333"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Topical therapy is the primary mode of treatment for plaque psoriasis in patients with limited skin involvement but is often insufficient for patients with moderate to severe plaque psoriasis (psoriasis involving more than 5 to 10 percent of the body surface area). (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Choice of therapy'</a>.)</p><p>The major treatment options for moderate to severe psoriasis include phototherapy and systemic medications. Selection among these treatments must involve consideration of the patient's comorbidities (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>).</p><p>The approach to the treatment of plaque psoriasis in adult patients with hepatitis B virus infection, hepatitis C virus infection, HIV infection, latent tuberculosis, and internal malignancy will be reviewed here. General reviews of plaque psoriasis therapy are provided separately. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/112983.html" rel="external">"Psoriasis in children: Management of chronic plaque psoriasis"</a>.)</p><p class="headingAnchor" id="H220664025"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The major categories of treatments for moderate to severe plaque psoriasis are listed below. Topical agents are often used in conjunction with these therapies (see  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultraviolet light phototherapy </strong>(see  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Narrowband ultraviolet B (UVB) phototherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Broadband UVB phototherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Psoralen plus ultraviolet A (PUVA) phototherapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral agents </strong>(see  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Systemic therapies'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">Apremilast</a> (phosphodiesterase-4 inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic agents</strong> (see  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Biologic agents'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">Etanercept</a> (tumor necrosis factor [TNF]-alpha inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a> (TNF-alpha inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> (TNF-alpha inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> (interleukin [IL] 12 and IL-23 inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> (IL-17A inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a> (IL-17A inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">Brodalumab</a> (IL-17RA inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">Guselkumab</a> (IL-23 inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">Tildrakizumab</a> (IL-23 inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">Risankizumab</a> (IL-23 inhibitor)</p><p></p><p>These therapies have side effects that can be detrimental in patients with certain underlying diseases. For example, the safety of a potentially hepatotoxic drug, such as <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, is a concern when treating patients with hepatitic disorders. In addition, the potential adverse effects of immunosuppressive therapy on patients with chronic infections or malignancies must be considered.</p><p>Selection of the optimal approach to treatment in patients with comorbidities, such as hepatitis B virus infection, hepatitis C virus infection, HIV infection, latent tuberculosis, and malignancy, is hampered by limited data on the safety of these treatments in the psoriasis population. Proposed guidelines have been based upon a combination of published data from patients with psoriasis, data from studies of similar treatment regimens for other diseases, and expert consensus (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>) [<a href="#rid1">1-7</a>]. </p><p class="headingAnchor" id="H9475340"><span class="h1">CHRONIC HEPATITIS B VIRUS INFECTION</span><span class="headingEndMark"> — </span>Hepatitis B virus (HBV) infection is one of the most common chronic viral infections in humans [<a href="#rid8">8,9</a>]. </p><p>HBV infection is divided into phases that reflect the interplay between virus replication and the host immune response (<a class="graphic graphic_figure graphicRef69344" href="/z/d/graphic/69344.html" rel="external">figure 1</a>). Laboratory studies are useful for determining the phase of the disease (<a class="graphic graphic_table graphicRef60627 graphicRef60827" href="/z/d/graphic/60627.html" rel="external">table 2A-B</a>). In patients with chronic HBV infection, hepatitis B surface antigen (HBsAg) and immunoglobulin G (IgG) hepatitis B core antibodies (IgG anti-HBc) persist in serum. Hepatitis e antigen (HBeAg), a marker of viral replication and infectivity that is usually associated with high levels of HBV DNA in serum and active liver disease, also may be detected. Upon recovery from HBV infection, HBsAg is no longer detectable in serum. However, patients with prior infection remain positive for IgG anti-HBc and are at risk for reactivation of disease during immunosuppressive therapy, particularly when hepatitis surface antibody (anti-HBs) negative. (See  <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history"</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H1550800224"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Overall, data on the safety of psoriasis therapies in patients with HBV infection are limited. Consideration of two factors is necessary for selection of a therapeutic agent:</p><p class="bulletIndent1"><span class="glyph">●</span>Does the therapy have direct hepatotoxic effects that can compound the existing viral liver disease?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the therapy have immunomodulatory effects that may promote viral replication and reactivation of HBV infection? (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p>In patients with moderate to severe plaque psoriasis and HBV infection, we use ultraviolet B (UVB) phototherapy (preferably narrowband UVB) supplemented with topical therapy as first-line treatment when it is available and convenient for the patient [<a href="#rid2">2</a>]. Narrowband UVB phototherapy is effective for psoriasis and has negligible risk for hepatotoxicity, systemic immunosuppression, or other systemic side effects. (See <a class="local">'Phototherapy'</a> below.)</p><p>If UVB phototherapy is not feasible, we consider systemic therapy (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). Preferred systemic therapies are <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> and <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, based upon the mechanism of action of apremilast and the availability of long-term safety data for ustekinumab (see <a class="local">'Ustekinumab'</a> below). <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> may also be well tolerated based upon their mechanisms of action, although cautious use of these drugs is indicated because of a paucity of safety data in this population. Selection amongst these systemic therapies is also based upon consideration of factors such as other comorbidities, clinician familiarity with specific agents, patient preference, treatment history, and treatment availability. (See <a class="local">'Biologic agents'</a> below and <a class="local">'Oral agents'</a> below and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.) </p><p class="headingAnchor" id="H174248504"><span class="h2">Phototherapy</span><span class="headingEndMark"> — </span>UVB phototherapy is generally considered safe in patients with HBV infection (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). Although the immunosuppressive effects of ultraviolet light are believed to contribute to the efficacy of UVB phototherapy in psoriasis and the risk for reactivation of HBV infection due to phototherapy has not been evaluated, the systemic effects of treatment are likely minimal [<a href="#rid2">2,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a>.)</p><p>The lack of need for topical or systemic administration of psoralens has led to a preference for UVB phototherapy (particularly narrowband UVB phototherapy) as the preferred mode of phototherapy for psoriasis. Although two one-year studies of patients without hepatitis failed to find statistically significant histologic differences in pre-psoralen plus ultraviolet A (PUVA) and post-PUVA liver biopsy specimens [<a href="#rid11">11,12</a>], there have been several reports of liver injury after PUVA therapy [<a href="#rid13">13-17</a>]. In addition, severe liver disease is a relative contraindication for treatment with PUVA (<a class="graphic graphic_table graphicRef83207" href="/z/d/graphic/83207.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p class="headingAnchor" id="H220663779"><span class="h2">Oral agents</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> is generally avoided in patients with HBV infection. Limited data suggest <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> is well tolerated. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> should be used with caution (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong> – Reactivation of HBV infection resulting in fulminant hepatic failure has been documented in case reports of patients treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for rheumatologic diseases [<a href="#rid18">18-21</a>]. This finding and the potential for methotrexate-induced hepatotoxicity raise concern about the safety of methotrexate therapy in patients with HBV infection, particularly given the existence of other therapeutic options. A 2012 consensus statement from the Medical Board of the National Psoriasis Foundation advised that methotrexate should <strong>not</strong> be prescribed in this population [<a href="#rid1">1,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acitretin</strong> –<strong> </strong><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> is not an immunosuppressant [<a href="#rid23">23,24</a>]. Therefore, despite a lack of data on the safety of acitretin use in HBV-infected patients, acitretin is not thought to increase the risk for reactivation of HBV infection. </p><p></p><p class="bulletIndent1">However, elevation of liver enzymes is a common side effect of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> [<a href="#rid25">25</a>], though severe hepatotoxic reactions are rare [<a href="#rid24">24,26</a>]. A two-year study of pretreatment and post-treatment liver biopsies in patients treated with acitretin for psoriasis failed to find clinically significant toxic effects on the liver, suggesting that hepatic tolerance of the drug may be good in healthy patients [<a href="#rid25">25</a>]. However, patients with chronic HBV infection may be more susceptible to hepatotoxic effects from acitretin; therefore, its use is not recommended. Patients treated with acitretin should be followed closely for laboratory evidence of liver toxicity and comanaged with a hepatologist. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Acitretin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apremilast</strong> –<strong> </strong>There are no known direct hepatotoxic effects of <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>. Although data on the effect of apremilast on HBV infection are lacking, the mechanism of action of apremilast suggests risk for reactivation of HBV infection may be low. Apremilast is considered one of the preferred treatment options in this patient population. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Apremilast'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> –<strong> </strong>The safety of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in patients with psoriasis and hepatitis B has not been specifically evaluated. Immunosuppressive properties of cyclosporine raise concern for the possibility of reactivation of HBV infection [<a href="#rid27">27,28</a>]. Caution is indicated for use of cyclosporine in patients with psoriasis and HBV infection. Patients should be managed in conjunction with a hepatologist, and initiation of antiviral therapy is recommended prior to treatment in HBsAg-positive patients. Close laboratory monitoring for signs of reactivation of infection should be performed during treatment; liver function tests and viral load should be routinely monitored. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is generally used as a short-term treatment (eg, up to 12 weeks); long-term use is avoided due to drug side effects. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Cyclosporine'</a>.)</p><p></p><p class="headingAnchor" id="H220663786"><span class="h2">Biologic agents</span><span class="headingEndMark"> — </span>The use of tumor necrosis factor (TNF)-alpha inhibitors (eg, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>) in patients with HBV infection is not recommended due to risk for reactivation of infection. Risk for reactivation of HBV infection appears to be low for <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>, and <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a>, which makes these biologics preferred over TNF inhibitors in patients with HBV infection (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>).</p><p>Patients requiring biologic therapies should be managed in conjunction with a hepatologist. Initiation of antiviral therapy is recommended prior to the start of biologic agents in HBsAg-positive patients [<a href="#rid1">1,29-31</a>]. In addition, close laboratory monitoring for signs of reactivation of infection is indicated during treatment; liver function tests and viral load should be routinely monitored [<a href="#rid1">1,4</a>]. </p><p class="headingAnchor" id="H3301166464"><span class="h3">Tumor necrosis factor-alpha inhibitors</span><span class="headingEndMark"> — </span>TNF-alpha inhibitors usually do not induce direct hepatotoxic effects [<a href="#rid32">32</a>]. Transaminase elevations develop only occasionally [<a href="#rid33">33</a>]. However, reactivation of HBV infection is the major concern with the use of TNF inhibitors, and their use is generally not recommended in patients with HBV infection.</p><p>Reactivation of HBV infection in patients treated with TNF-alpha inhibitors may be related to a suppressive role of endogenous TNF-alpha on replication of HBV [<a href="#rid4">4</a>]. HBsAg-positive patients have the greatest risk for disease reactivation. Reactivation occurs less frequently in HBsAg-negative patients who have a prior history of HBV infection and is rare in HBsAg-negative patients who have achieved full immunologic recovery (anti-HBs-positive and anti-HBc-positive (<a class="graphic graphic_table graphicRef60827" href="/z/d/graphic/60827.html" rel="external">table 2B</a>)) [<a href="#rid4">4,32,34</a>]. </p><p>The lack of clarity on the level of risk for HBV reactivation due to TNF-alpha inhibitor therapy for psoriasis reflects the consistent exclusion of patients with HBV infection from trials evaluating the efficacy and safety of these therapies. Reactivation of HBV infection in HBsAg-positive patients treated with TNF-alpha inhibitors for psoriasis has been reported [<a href="#rid35">35</a>]. As an example, in one series of seven HBsAg-positive patients with psoriasis or psoriatic arthritis who were treated with <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> for an average of 29 months, three patients, including one who had undetectable HBV DNA levels prior to treatment, developed reactivation of HBV infection [<a href="#rid36">36</a>]. Antiviral prophylaxis was given to only one patient; reactivation of HBV infection did not occur in this patient. </p><p>As a result of the paucity of treatment data in patients with moderate to severe psoriasis and HBV infection, much of the knowledge of the use of these agents in the setting of HBV infection stems from literature published in patients with conditions other than psoriasis. Most reported cases of HBV reactivation have occurred in patients who were taking <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for rheumatologic conditions [<a href="#rid37">37,38</a>], suggesting that infliximab may be the TNF-alpha inhibitor that is most likely to cause HBV reactivation. It is unclear whether the disproportionate number of reports for infliximab compared with other TNF-alpha inhibitors is related to its longer half-life or greater drug potency [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Etanercept'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Infliximab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Adalimumab'</a>.)</p><p class="headingAnchor" id="H1503282"><span class="h3">Ustekinumab</span><span class="headingEndMark"> — </span>Long-term data on <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> have not shown an increase in HBV reactivation rates [<a href="#rid35">35</a>]. Antiviral prophylaxis may be important in HBsAg-positive patients [<a href="#rid30">30,31</a>]. In a retrospective study of patients treated with ustekinumab for psoriasis, reactivation of HBV infection occurred in two of seven HBsAg-positive patients who did not receive antiviral prophylaxis, whereas none of four HBsAg-positive patients given antiviral prophylaxis developed reactivation [<a href="#rid31">31</a>]. Of note, reactivation of HBV infection also has been documented in a patient who was HBsAg-negative, anti-HBc-positive, and anti-HBs-positive prior to ustekinumab therapy [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ustekinumab'</a>.)</p><p class="headingAnchor" id="H3560269583"><span class="h3">Secukinumab, ixekizumab, and brodalumab</span><span class="headingEndMark"> — </span>Clinical data on the effect of interleukin (IL) 17 inhibitors on reactivation of HBV infection are limited to case reports [<a href="#rid40">40</a>]. For example, based on case reports, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> has been used in patients with HBV and hepatitis C virus (HCV) infection without viral reactivation or significant elevations in liver enzymes [<a href="#rid40">40</a>]. The mechanism of effect of IL-17 inhibitors in patients with viral hepatitis is unknown. Thus, the benefit/risk assessment needs to be carefully considered when using IL-17 inhibitors in patients with viral hepatitis. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Secukinumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ixekizumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Brodalumab'</a>.)  </p><p class="headingAnchor" id="H3764385042"><span class="h3">Guselkumab, tildrakizumab, and risankizumab</span><span class="headingEndMark"> — </span>The effects of <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>, and <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a> on psoriasis patients with HBV infection are unknown due to excluding patients with active hepatitis B from phase II and III studies. The use of IL-23 inhibitors must be carefully monitored in patients with viral hepatitis. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Guselkumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Tildrakizumab'</a>.)</p><p class="headingAnchor" id="H9475347"><span class="h1">CHRONIC HEPATITIS C VIRUS INFECTION</span><span class="headingEndMark"> — </span>Hepatitis C is a common blood-borne infection [<a href="#rid41">41</a>]. Similar to hepatitis B virus (HBV) infection, the primary concerns for the treatment of moderate to severe psoriasis in hepatitis C virus (HCV)-infected patients are exacerbation of the infection and drug-induced hepatotoxicity. Of note, interferon, a treatment for HCV infection, may exacerbate psoriasis [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Introduction'</a>.)</p><p class="headingAnchor" id="H3297164991"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Patients with HCV infection should be referred to a hepatologist for evaluation, particularly given the existence of treatments that can eradicate the infection. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p>The paucity of data on the treatment of psoriasis in patients with HCV infection makes the identification of the best approach to the treatment difficult. Ultraviolet B (UVB) phototherapy in combination with topical therapy is considered safe and a preferred treatment for patients with moderate to severe psoriasis and HCV infection [<a href="#rid3">3</a>]. Other treatment options that are likely to be well tolerated include tumor necrosis factor (TNF)-alpha inhibitors, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> based on the mechanisms of action of these drugs or evidence that suggests low risk for hepatotoxicity or exacerbation of HCV infection. Use of newer biologic agents, including <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>, may also be well tolerated, though a cautious approach is indicated because of limited experience with these agents in patients with HCV infection. Selection amongst the systemic therapies is also based upon consideration of factors such as other comorbidities, clinician familiarity with specific agents, patient preference, treatment history, and treatment availability (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). (See <a class="local">'Phototherapy'</a> below and <a class="local">'Biologic agents'</a> below.)</p><p class="headingAnchor" id="H974087"><span class="h2">Phototherapy</span><span class="headingEndMark"> — </span>Although the safety of phototherapy in patients with HCV infection has not been specifically studied, UVB phototherapy generally is considered safe in these patients (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. Psoralen plus ultraviolet A (PUVA) is an additional therapeutic option; however, there have been several reports of liver injury after PUVA therapy [<a href="#rid13">13-17</a>], and severe liver disease is considered a relative contraindication for PUVA (<a class="graphic graphic_table graphicRef83207" href="/z/d/graphic/83207.html" rel="external">table 3</a>). (See <a class="local">'Phototherapy'</a> above and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p></p><p class="headingAnchor" id="H220663801"><span class="h2">Oral agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> are generally avoided in patients with HCV infection due to safety concerns. Limited data suggest that <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> is well tolerated. Caution is necessary for the use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong> –<strong> </strong><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is contraindicated for the treatment of psoriasis in patients with HCV infection due to an increased risk for hepatotoxicity [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acitretin</strong> – The safety of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> in patients with HCV infection has not been studied. Liver function test abnormalities, and occasionally long-term hepatotoxic effects, can occur during treatment [<a href="#rid25">25</a>]. A two-year study of pretreatment and post-treatment liver biopsies in patients without hepatitis who were treated with acitretin for psoriasis failed to find clinically significant toxic effects on the liver [<a href="#rid25">25</a>]. Nevertheless, due to the potential for hepatotoxicity, we do not use acitretin unless other therapeutic options are not feasible. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Acitretin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apremilast</strong> – There are no known direct hepatotoxic effects of <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>. A case report describes successful use in a patient with HCV and HIV infections [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Apremilast'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> – Traditionally, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> has been avoided in the treatment of psoriasis in patients with HCV infection due to concerns that the drug's immunosuppressive effects might exacerbate the infection [<a href="#rid3">3</a>]. However, in vitro studies have found that cyclosporine has suppressive effects on HCV replication [<a href="#rid44">44-46</a>]. In addition, case reports have documented improvements in both transaminase levels and psoriasis during treatment with cyclosporine in patients with HCV infection [<a href="#rid47">47-50</a>]. These findings suggest that cyclosporine therapy may be tolerated in patients with psoriasis and HCV infection. Consultation with a hepatologist should be performed prior to starting treatment with cyclosporine. In addition, periodic laboratory assessment for signs of reactivating disease is warranted. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Cyclosporine'</a>.)</p><p></p><p class="headingAnchor" id="H220663808"><span class="h2">Biologic agents</span><span class="headingEndMark"> — </span>Consultation with a hepatologist should be performed prior to starting treatment with a biologic agent in patients with moderate to severe psoriasis and HCV infection. In addition, biologic therapy should be accompanied by regular monitoring of viral hepatitis activity [<a href="#rid1">1,32</a>]. TNF inhibitors and <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> appear to be well tolerated provided liver function enzymes and viral load are monitored. </p><p>Data on interleukin (IL) 17 and IL-23 inhibitors are lacking in patients with HCV infection. While the mechanisms of these drugs do not suggest substantial adverse effects, due to the lack of data in this population, clinicians should use them with caution. Liver function enzymes and viral activity should be monitored (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H106913731"><span class="h3">Tumor necrosis factor-alpha inhibitors</span><span class="headingEndMark"> — </span>Although data on biologic therapy in patients with HCV infection are limited, the available data from studies in patients with psoriasis and other diseases suggest that patients with chronic HCV infection may tolerate TNF-alpha inhibitor therapy [<a href="#rid35">35</a>]. Interestingly, a small randomized trial found that patients who were given <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> as an adjunct to interferon and <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for the treatment of HCV infection were more likely to achieve clearance of HCV RNA than patients who received interferon, ribavirin, and a placebo [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections", section on 'Hepatitis C'</a>.)</p><p>Data on the use of <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, the biologic agent most studied in patients with psoriasis and HCV infection, primarily consist of case reports and small retrospective studies. A systematic review of published reports between 1990 and 2010 identified 22 case reports of patients treated with etanercept for psoriasis or psoriatic arthritis [<a href="#rid52">52</a>]. The review found that viral loads or transaminase levels remained stable in 17 of these patients and decreased in 4 patients during treatment with etanercept. Only one patient developed an increase in viral load. </p><p>Additional case reports and small retrospective studies have documented successful use of <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for psoriasis in patients with HCV infection [<a href="#rid35">35,52-60</a>]. As an example, a retrospective study of 20 adults with psoriasis and HCV infection who were treated with etanercept (18 patients), adalimumab (4 patients), <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> (3 patients), and/or infliximab (1 patient), found that these biologic agents were well tolerated by most patients [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Etanercept'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Infliximab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Adalimumab'</a>.)</p><p class="headingAnchor" id="H1504190"><span class="h3">Ustekinumab</span><span class="headingEndMark"> — </span>Data on the use of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> in patients with HCV infection and psoriasis are limited [<a href="#rid30">30,31</a>]. Long-term studies have not shown an increase in HCV reactivation rates in patients treated with ustekinumab [<a href="#rid31">31,61</a>]. However, close monitoring and collaboration with a hepatologist are indicated during treatment with ustekinumab for following HCV disease progression.</p><p class="headingAnchor" id="H3691771838"><span class="h3">Secukinumab, ixekizumab, and brodalumab</span><span class="headingEndMark"> — </span>Safety data on the use of IL-17 inhibitors in HCV-infected patients are lacking because the phase II and III trials excluded patients with active hepatitis C. However, there are no biologic mechanisms or postmarketing data suggesting increased risk associated with use of IL-17 inhibitors in this population. Patients treated with IL-17 inhibitors should be routinely monitored for viral hepatitis activity. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Secukinumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ixekizumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Brodalumab'</a>.)</p><p class="headingAnchor" id="H2227722977"><span class="h3">Guselkumab, tildrakizumab, and risankizumab</span><span class="headingEndMark"> — </span>Safety data on the use of the IL-23 inhibitors <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>, and <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a> in hepatitis C patients are lacking. However, there are no biologic mechanisms or postmarketing data suggesting increased risk associated with use of these drugs in the setting of HCV infection. Patients treated with guselkumab, tildrakizumab, or risankizumab should be routinely monitored for viral hepatitis activity. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Guselkumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Tildrakizumab'</a>.)</p><p class="headingAnchor" id="H9475354"><span class="h1">HIV INFECTION</span><span class="headingEndMark"> — </span>HIV infection is a risk factor for severe psoriasis [<a href="#rid6">6</a>]. In some patients, psoriasis is the initial presenting sign of HIV infection [<a href="#rid5">5</a>]. The immunosuppressive effects of psoriasis therapies are the major concern in this population.</p><p class="headingAnchor" id="H1920677557"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Patients with HIV infection and moderate to severe psoriasis are best managed by coordinated care with a dermatologist and infectious disease specialist. The Medical Board of the National Psoriasis Foundation recommends phototherapy and antiretrovirals as first-line therapies for patients with HIV infection and moderate to severe psoriasis, and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> is an appropriate second-line treatment [<a href="#rid6">6</a>]. Recommendations in a 2015 update to the European S3-Guidelines are fairly similar, supporting antiretroviral therapy plus skin-directed treatments, such as phototherapy and topical agents, as first-line treatments and acitretin plus antiretroviral therapy as second-line treatment [<a href="#rid62">62</a>]. </p><p>Our typical first-line therapeutic approach to moderate to severe psoriasis in patients with HIV infection consists of antiretroviral treatment along with phototherapy supplemented with topical therapy. However, multiple phototherapy visits are inconvenient for many patients. <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> supplemented with topical medication or <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> supplemented with topical medication are well-tolerated alternatives to phototherapy (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>).</p><p>Therapies such as <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and biologic drugs (tumor necrosis factor [TNF]-alpha inhibitors, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, and <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>) should be reserved for refractory cases and should be used cautiously; the status of the HIV infection should be monitored closely during treatment.</p><p class="headingAnchor" id="H515703"><span class="h2">Antiretroviral drugs</span><span class="headingEndMark"> — </span>Psoriasis in HIV-infected patients may improve with antiretroviral therapy [<a href="#rid5">5,63-68</a>]. As an example, in an open-label study in which 24 patients with HIV-associated psoriasis were treated with <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, 90 percent of the 19 patients who were followed for at least eight weeks achieved either partial or complete improvement of psoriasis [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H220663823"><span class="h2">Phototherapy</span><span class="headingEndMark"> — </span>Phototherapy can be effective for HIV-associated psoriasis [<a href="#rid2">2,69-71</a>]. Although ultraviolet radiation has been linked to activation of HIV in some in vitro and animal studies [<a href="#rid72">72-74</a>], small case series and uncontrolled studies suggest that phototherapy administered to HIV-positive patients is well tolerated and not associated with significant changes in viral load, CD4+, and CD8+ T cells during or after therapy [<a href="#rid69">69,71,75,76</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a>.)</p><p class="headingAnchor" id="H220663830"><span class="h2">Oral agents</span><span class="headingEndMark"> — </span>Patients with HIV infection typically tolerate <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>. <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> must be used with caution (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acitretin</strong> –<strong> </strong><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> is an attractive therapeutic option for psoriasis in patients with HIV infection because it is not an immunosuppressant. In a 20-week uncontrolled study in which 11 HIV-positive men with moderate to severe psoriasis (including seven men with plaque-type psoriasis) were treated with acitretin (up to 100 mg per day), four patients achieved at least 75 percent reduction in the Psoriasis Area and Severity Index (PASI) score, and an additional two patients achieved at least 51 to 75 percent improvement. Two of the three patients who discontinued treatment stopped treatment due to worsening psoriasis. The third patient stopped treatment due to a myocardial infarction that was presumed to be unrelated to acitretin therapy [<a href="#rid77">77</a>]. Of note, typical doses of acitretin for the treatment of psoriasis range from 25 to 50 mg per day; higher doses are often poorly tolerated due to side effects. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Acitretin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong> – <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is not commonly used for psoriasis in HIV-infected patients due to concern about the drug's immunosuppressive effects [<a href="#rid5">5,69,78</a>]. Although case reports have documented successful treatment in the setting of HIV infection [<a href="#rid78">78</a>], the risks and benefits of therapy must be weighed carefully prior to treatment [<a href="#rid5">5</a>]. Treatment with methotrexate is usually reserved for refractory cases. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apremilast</strong> – <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">Apremilast</a> is considered a treatment option for HIV-infected patients because it does not appear to have significant immunosuppressive effects [<a href="#rid79">79</a>]. Treatment was well tolerated in a patient with HIV and hepatitis C virus (HCV) infections [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Apremilast'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> –<strong> </strong>Case reports have documented the successful use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for psoriasis in patients with HIV infection [<a href="#rid80">80,81</a>]. However, as with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, the immunosuppressive effects are a concern. Treatment with cyclosporine is primarily reserved for short courses (up to 12 weeks) of treatment in patients with refractory disease. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Cyclosporine'</a>.)</p><p></p><p class="bulletIndent1">Some authors have suggested an initial starting dose of 2.5 mg/kg per day of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> if the drug is used in this population [<a href="#rid5">5</a>]. Trough levels of cyclosporine should be monitored carefully in patients taking protease inhibitors, since these agents may increase the bioavailability of cyclosporine [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H220663844"><span class="h2">Biologic agents</span><span class="headingEndMark"> — </span>Data are limited on the safety of biologic therapies in patients with HIV infection. Several cases of successful use of biologic TNF-alpha inhibitors for psoriasis or rheumatologic conditions in patients with HIV infection have been reported [<a href="#rid83">83-87</a>]. Viral counts and immune status remained stable in these patients. However, one report documented the eventual discontinuation of <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> due to the occurrence of multiple infections [<a href="#rid87">87</a>].</p><p>An additional case report has described successful treatment of psoriasis with <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> [<a href="#rid88">88</a>]. The patient achieved great improvement in psoriasis, and treatment was well tolerated.</p><p>Tolerance of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> in the setting of HIV infection has not been evaluated. The mechanisms of action of these drugs suggest risk for exacerbation of HIV infection would be low.  </p><p>Further studies are necessary to determine the role biologic therapy should play in the management of psoriasis in patients with HIV infection (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). In general, these agents should be used with caution and reserved for HIV-infected patients who cannot be adequately treated with preferred therapies, are receiving antiretroviral therapy, and can be regularly monitored. Concomitant antiretroviral therapy is suggested to decrease the likelihood of opportunistic infections during biologic treatment [<a href="#rid5">5,6,83,89</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Biologic agents'</a>.)</p><p class="headingAnchor" id="H515897"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Other drugs that have been reported to be useful in individual patients with HIV infection and psoriasis include <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">ranitidine</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, antibiotics, <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">nicotinamide</a>, and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [<a href="#rid5">5</a>]. Ranitidine has been withdrawn from the United States market.</p><p class="headingAnchor" id="H9475361"><span class="h1">LATENT TUBERCULOSIS</span><span class="headingEndMark"> — </span>Immunosuppressive treatment may result in reactivation of latent tuberculosis (TB) infection. Thus, screening for TB infection is recommended prior to the administration of immunosuppressive therapies for psoriasis (eg, biologic agents, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) [<a href="#rid7">7,62,90</a>]. These drugs should be used with caution (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). Tumor necrosis factor (TNF)-alpha plays a particularly important role in the immune defense against TB infection, raising particular concern about the use of TNF-alpha inhibitor therapy. Use of therapies without systemic immunosuppressive effects, such as phototherapy, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, are not considered to increase risk for TB reactivation (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.) </p><p>Screening for TB is performed through a patient interview and testing via a <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or interferon-gamma release assay. A chest radiograph should be performed if the screening test is positive. Screening for TB infection is not necessary prior to treatment with topical agents, phototherapy, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, or <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> since these therapies do not appear to increase the risk for reactivation of TB infection. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p>Patients who have latent TB should be given treatment for this condition to reduce the risk for TB [<a href="#rid91">91,92</a>]. Opinions vary on how long patients must be on treatment for latent TB before TNF-alpha inhibitor therapy can be initiated. While some authors recommend completing the full course of prophylactic TB therapy prior to biologic therapy [<a href="#rid93">93</a>], other sources, including the Medical Board of the National Psoriasis Foundation, suggest initiation of immunologic therapies after the first one to two months of prophylactic TB treatment if it is required by the clinical condition [<a href="#rid2">2,7,94,95</a>]. </p><p>We agree with the National Psoriasis Foundation's approach. While the full course of prophylactic TB treatment can be completed before initiating a biologic agent, we consider acceptable the initiation of biologic therapy following at least one month of TB treatment, such that the patient will then continue TB treatment concurrently with biologic therapy. (See  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p>The risk for TB reactivation among patients who are treated with prophylactic therapy prior to the start of biologic therapy appears to be low [<a href="#rid91">91,96-100</a>]. As an example, in an analysis of data from five phase III trials of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> therapy for moderate to severe plaque psoriasis, none of the 167 patients with newly diagnosed latent TB infection who began TB prophylaxis before or at the time of the first dose of ustekinumab developed active TB during a 28-week follow-up period [<a href="#rid97">97</a>]. The risk for mycobacterial infections in patients treated with TNF-alpha inhibitors is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p class="headingAnchor" id="H9475368"><span class="h1">MALIGNANCY</span><span class="headingEndMark"> — </span>The immunosuppressive effects of systemic agents for psoriasis are the primary safety concerns for systemic psoriasis therapy in patients with a history of internal malignancy. The best approach to the treatment varies based upon the severity of psoriasis and the type of malignancy (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>). Consultation with the patient's oncologist and a thorough discussion with the patient about the risk-benefit ratios of the therapeutic options should take place prior to deciding on a treatment. </p><p><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may increase the risk for lymphoproliferative disorders. In long-term studies in the psoriasis population, tumor necrosis factor inhibitors and <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> do not appear to increase risk for internal malignancies. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Risk of malignancy'</a> and  <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a> and  <a class="medical medical_review" href="/z/d/html/15278.html" rel="external">"Comorbid disease in psoriasis", section on 'Malignancy'</a> and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Risk of lymphoproliferative disorders'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ustekinumab'</a>.)</p><p>Data have not shown an association between internal malignancies and the use of interleukin (IL) 17 inhibitors, such as <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> [<a href="#rid101">101,102</a>], <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> [<a href="#rid103">103</a>], or <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> [<a href="#rid104">104</a>]. Similarly, short-term data have not shown an association between internal malignancies and IL-23 inhibitors, such as <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> [<a href="#rid105">105</a>], <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> [<a href="#rid106">106</a>], and <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a> [<a href="#rid107">107</a>].</p><p>Nonimmunosuppressive therapies, such as phototherapy and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, are generally considered safe treatment options for patients with current or prior hematologic or solid tumor malignancies [<a href="#rid2">2,62</a>]. Patients with a history of melanoma or multiple nonmelanoma skin cancers are an exception since these conditions are relative contraindications for phototherapy [<a href="#rid10">10</a>]. Of note, patients with a history of multiple squamous cell skin cancers may benefit from the suppressive effect of acitretin on the development of these lesions. (See  <a class="medical medical_review" href="/z/d/html/128194.html" rel="external">"Cutaneous squamous cell carcinoma: Primary and secondary prevention", section on 'Oral retinoids'</a>.)</p><p>Long-term data on the risk of malignancy and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> are not available. Short-term data do not suggest a link between internal malignancy and apremilast [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H39205739"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The management of psoriasis in pregnant women is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5663.html" rel="external">"Management of psoriasis in pregnancy"</a>.)</p><p class="headingAnchor" id="H3210127246"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112498.html" rel="external">"Society guideline links: Psoriasis"</a>.)</p><p class="headingAnchor" id="H52453712"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with moderate to severe psoriasis (psoriasis involving more than 5 to 10 percent of the body surface area) generally require phototherapy, oral medications (eg, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>), or biologics (eg, tumor necrosis factor [TNF]-alpha inhibitors, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, interleukin [IL] 17 inhibitors, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>) for optimal management of the disease. The potential adverse effects of these therapies must be considered carefully in patients with comorbidities. (See <a class="local">'Overview'</a> above and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Choice of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The determination of the best approach to the management of psoriasis in patients with hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, HIV infection, latent tuberculosis (TB), and internal malignancy is challenging because data on psoriasis therapy in these populations are limited. Recommendations for the management of these patients are based upon data from patients with psoriasis, patients with other disorders treated with similar therapies, and expert opinion (<a class="graphic graphic_table graphicRef115587" href="/z/d/graphic/115587.html" rel="external">table 1</a>) (see <a class="local">'Overview'</a> above and <a class="local">'Chronic hepatitis B virus infection'</a> above and <a class="local">'Chronic hepatitis C virus infection'</a> above and <a class="local">'HIV infection'</a> above and <a class="local">'Latent tuberculosis'</a> above and <a class="local">'Malignancy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Narrowband ultraviolet B (UVB) phototherapy</strong> – Narrowband UVB phototherapy has negligible effects on hepatic tissue and systemic immunity. Narrowband UVB phototherapy is a safe treatment for psoriasis in patients with HBV infection, HCV infection, HIV infection, latent TB, and internal malignancy. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acitretin</strong> – <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> lacks immunosuppressive effects and is typically well tolerated by patients with HIV infection, latent TB, or malignancy. However, acitretin may have adverse hepatic effects and is generally avoided in the setting of HBV or HCV infection. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Acitretin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methotrexate</strong> – <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> has hepatotoxic and immunosuppressive effects and is not recommended for the treatment of psoriasis in patients with HBV or HCV infection. In patients with HIV infection or latent TB, methotrexate should be used with caution. Methotrexate may increase risk for lymphoproliferative disorders. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cyclosporine</strong> –<strong> </strong><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> has immunosuppressive effects. The drug should be used with caution; consultation with disease specialists and close monitoring are indicated for patients with viral hepatitis, HIV, latent TB, or malignancy. Long-term use of cyclosporine is generally not recommended due to renal toxicity. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Cyclosporine'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Apremilast</strong> –<strong> </strong><a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">Apremilast</a> appears to have minimal immunosuppressive effects. Apremilast is one of the preferred therapies for psoriasis in patients with HBV infection, HCV infection, HIV infection, and latent tuberculosis. Short-term data do not suggest an increased risk of malignancy with apremilast. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Apremilast'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TNF-alpha inhibitors</strong> – TNF-alpha inhibitors are generally avoided in patients with HBV infection due to concerns for disease reactivation. In contrast, TNF-alpha inhibitor therapy is one of the preferred biologic therapies for patients with HCV infection provided consultation with a hepatologist and close monitoring are feasible. TNF-alpha inhibitors should be used with caution and in conjunction with antiviral therapy and anti-TB therapy in patients with HIV infection and latent TB, respectively. TNF-alpha inhibitors do not increase risk for malignancy in the psoriasis population. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Etanercept'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Infliximab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Adalimumab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ustekinumab</strong> –<strong> </strong><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> is a preferred biologic therapy in patients with HBV or HCV infection provided consultation with a hepatologist and close monitoring are feasible. Among patients with HIV infection, ustekinumab is primarily reserved for refractory psoriasis in patients who can be closely monitored for HIV activity. Ustekinumab is a preferred biologic agent for patients with latent TB provided patients also receive anti-TB therapy. Ustekinumab does not increase risk of internal malignancy in the psoriasis population. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ustekinumab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IL-17 inhibitors, </strong><strong>guselkumab</strong><strong>, and </strong><strong>tildrakizumab</strong> – Caution is indicated for use of IL-17 inhibitors (<a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>), <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> in patients with HBV, HCV, or HIV infection because of a lack of long-term data. Consultation with disease specialists and close monitoring are indicated. IL-17 inhibitors, guselkumab, and tildrakizumab are considered preferred biologic therapies in patients with latent TB provided patients also receive anti-TB therapy. Short-term studies have not found increased risk of internal malignancy in psoriasis patients treated with IL-17 inhibitors, guselkumab, or tildrakizumab. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Secukinumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ixekizumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Brodalumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Guselkumab'</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Tildrakizumab'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148:95.</a></li><li><a class="nounderline abstract_t">Strober B, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol 2009; 61:S1.</a></li><li><a class="nounderline abstract_t">Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 61:1044.</a></li><li><a class="nounderline abstract_t">Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol 2012; 67:1349.</a></li><li><a class="nounderline abstract_t">Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 2010; 10:470.</a></li><li><a class="nounderline abstract_t">Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:291.</a></li><li><a class="nounderline abstract_t">Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59:209.</a></li><li><a class="nounderline abstract_t">Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 Suppl 1:S64.</a></li><li><a class="nounderline abstract_t">Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26:628.</a></li><li><a class="nounderline abstract_t">Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.</a></li><li><a class="nounderline abstract_t">Zachariae H, Kragballe K, Søgaard H. Liver biopsy in PUVA-treated patients. Acta Derm Venereol 1979; 59:268.</a></li><li><a class="nounderline abstract_t">Nyfors A, Dahl-Nyfors B, Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986; 14:43.</a></li><li><a class="nounderline abstract_t">Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). J Am Acad Dermatol 1980; 3:248.</a></li><li><a class="nounderline abstract_t">Markin RS, Donovan JP, Shaw BW Jr, Zetterman RK. Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis. J Clin Gastroenterol 1993; 17:311.</a></li><li><a class="nounderline abstract_t">Bjellerup M, Bruze M, Krook G, Ljunggren B. Toxic hepatitis after PUVA. J Am Acad Dermatol 1981; 4:481.</a></li><li><a class="nounderline abstract_t">Stephens RB, Cooper A. Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis. Australas J Dermatol 1999; 40:217.</a></li><li><a class="nounderline abstract_t">Bjellerup M, Bruze M, Hansson A, et al. Liver injury following administration of 8-methoxypsoralen during PUVA therapy. Acta Derm Venereol 1979; 59:371.</a></li><li><a class="nounderline abstract_t">Watanabe K, Takase K, Ohno S, et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 2012; 22:470.</a></li><li><a class="nounderline abstract_t">Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007; 25:888.</a></li><li><a class="nounderline abstract_t">Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112:381.</a></li><li><a class="nounderline abstract_t">Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44:339.</a></li><li><a class="nounderline abstract_t">King LE. Letter: Complications during methotrexate therapy for psoriasis. Arch Dermatol 1975; 111:131.</a></li><li><a class="nounderline abstract_t">Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf 2009; 8:769.</a></li><li><a class="nounderline abstract_t">Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41:S7.</a></li><li><a class="nounderline abstract_t">Roenigk HH Jr, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999; 41:584.</a></li><li><a class="nounderline abstract_t">van Ditzhuijsen TJ, van Haelst UJ, van Dooren-Greebe RJ, et al. Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 1990; 11:185.</a></li><li><a class="nounderline abstract_t">Sandrini S, Callea F, Cristinelli L, et al. Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids. Nephrol Dial Transplant 1990; 5:525.</a></li><li><a class="nounderline abstract_t">Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12:51.</a></li><li><a class="nounderline abstract_t">Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25:471.</a></li><li><a class="nounderline abstract_t">Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168:609.</a></li><li><a class="nounderline abstract_t">Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013; 169:1295.</a></li><li><a class="nounderline abstract_t">Viganò M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12:193.</a></li><li><a class="nounderline abstract_t">Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:1612.</a></li><li><a class="nounderline abstract_t">Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25:285.</a></li><li><a class="nounderline abstract_t">Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol 2017; 77:88.</a></li><li><a class="nounderline abstract_t">Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2012; 39:269.</a></li><li><a class="nounderline abstract_t">Stine JG, Bass M, Ibrahim D, et al. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy. South Med J 2011; 104:781.</a></li><li><a class="nounderline abstract_t">Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159:1217.</a></li><li><a class="nounderline abstract_t">Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 2013; 168:679.</a></li><li><a class="nounderline abstract_t">Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol 2018; 32:e120.</a></li><li class="breakAll">Lanvanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Hepatitis C, Liang TJ, Hoofnagle JH (Eds), Academic Press, San Diego 2000. p.185.</li><li><a class="nounderline abstract_t">Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2013; 27:771.</a></li><li><a class="nounderline abstract_t">Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol 2017; 31:e481.</a></li><li><a class="nounderline abstract_t">Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282.</a></li><li><a class="nounderline abstract_t">Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313:42.</a></li><li><a class="nounderline abstract_t">Liu JP, Ye L, Wang X, et al. Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl Infect Dis 2011; 13:24.</a></li><li><a class="nounderline abstract_t">Bomm L, Zimmermann C, Souto R, et al. Use of cyclosporin in a patient with hepatitis C and pustular psoriasis. An Bras Dermatol 2011; 86:S193.</a></li><li><a class="nounderline abstract_t">Di Lernia V. Treatment of psoriasis in patients with hepatitis C virus infection. Clin Exp Dermatol 2011; 36:417.</a></li><li><a class="nounderline abstract_t">Giovanna Brunasso AM, Michetti P, Fancelli L, Massone C. Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option. Hepat Mon 2012; 12:349.</a></li><li><a class="nounderline abstract_t">Imafuku S, Tashiro A, Furue M. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol 2007; 156:1367.</a></li><li><a class="nounderline abstract_t">Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42:315.</a></li><li><a class="nounderline abstract_t">Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50:1700.</a></li><li><a class="nounderline abstract_t">De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54:1102.</a></li><li><a class="nounderline abstract_t">Di Lernia V, Guareschi E. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J 2010; 16:8.</a></li><li><a class="nounderline abstract_t">Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51:580.</a></li><li><a class="nounderline abstract_t">Prignano F, Ricceri F, Pescitelli L, et al. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011; 164:645.</a></li><li><a class="nounderline abstract_t">Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26:261.</a></li><li><a class="nounderline abstract_t">Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007; 32:18.</a></li><li><a class="nounderline abstract_t">Zanni M, Missale G, Santilli D, Di Nuzzo S. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol 2011; 21:564.</a></li><li><a class="nounderline abstract_t">Gandhi RK, Pickup T, Sheth PB. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010; 146:1151.</a></li><li><a class="nounderline abstract_t">Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22:6444.</a></li><li><a class="nounderline abstract_t">Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29:2277.</a></li><li><a class="nounderline abstract_t">Duvic M, Crane MM, Conant M, et al. Zidovudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol 1994; 130:447.</a></li><li><a class="nounderline abstract_t">Fischer T, Schwörer H, Vente C, et al. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. AIDS 1999; 13:628.</a></li><li><a class="nounderline abstract_t">Mahajan VK, Sharma NL, Sarin S, et al. Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience. J Eur Acad Dermatol Venereol 2008; 22:1017.</a></li><li><a class="nounderline abstract_t">Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 2006; 38:74.</a></li><li><a class="nounderline abstract_t">Kaplan MH, Sadick NS, Wieder J, et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. J Am Acad Dermatol 1989; 20:76.</a></li><li><a class="nounderline abstract_t">Arnett FC, Reveille JD, Duvic M. Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am 1991; 17:59.</a></li><li><a class="nounderline abstract_t">Breuer-McHam J, Marshall G, Adu-Oppong A, et al. Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. J Am Acad Dermatol 1999; 40:48.</a></li><li><a class="nounderline abstract_t">Chernyshov P. Testing for HIV prior to methotrexate administration. Is it an obligatory procedure? Int J Dermatol 2006; 45:998.</a></li><li><a class="nounderline abstract_t">Meola T, Soter NA, Ostreicher R, et al. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol 1993; 29:216.</a></li><li><a class="nounderline abstract_t">Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol Today 1990; 11:176.</a></li><li><a class="nounderline abstract_t">Cavard C, Zider A, Vernet M, et al. In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat. J Clin Invest 1990; 86:1369.</a></li><li><a class="nounderline abstract_t">Stein B, Krämer M, Rahmsdorf HJ, et al. UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells. J Virol 1989; 63:4540.</a></li><li><a class="nounderline abstract_t">Fotiades J, Lim HW, Jiang SB, et al. Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus. Photodermatol Photoimmunol Photomed 1995; 11:107.</a></li><li><a class="nounderline abstract_t">Pechère M, Yerly S, Lemonnier E, et al. Impact of PUVA therapy on HIV viremia: a pilot study. Dermatology 1997; 195:84.</a></li><li><a class="nounderline abstract_t">Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133:711.</a></li><li><a class="nounderline abstract_t">Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994; 31:372.</a></li><li><a class="nounderline abstract_t">Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77:310.</a></li><li><a class="nounderline abstract_t">Allen BR. Use of cyclosporin for psoriasis in HIV-positive patient. Lancet 1992; 339:686.</a></li><li><a class="nounderline abstract_t">Tourne L, Durez P, Van Vooren JP, et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol 1997; 37:501.</a></li><li><a class="nounderline abstract_t">Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62:838.</a></li><li><a class="nounderline abstract_t">Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007; 74:197.</a></li><li><a class="nounderline abstract_t">Bartke U, Venten I, Kreuter A, et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004; 150:784.</a></li><li><a class="nounderline abstract_t">Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710.</a></li><li><a class="nounderline abstract_t">Lee ES, Heller MM, Kamangar F, et al. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. J Drugs Dermatol 2012; 11:413.</a></li><li><a class="nounderline abstract_t">Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75:1093.</a></li><li><a class="nounderline abstract_t">Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat 2012; 23:398.</a></li><li><a class="nounderline abstract_t">Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012; 59:C4480.</a></li><li><a class="nounderline abstract_t">Ahn CS, Dothard EH, Garner ML, et al. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 2015; 73:420.</a></li><li><a class="nounderline abstract_t">Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766.</a></li><li><a class="nounderline abstract_t">Perez J, Kupper H, Spencer-Green G. Impact of screening for latent TB prior to initiation of anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64:86.</a></li><li><a class="nounderline abstract_t">Sivamani RK, Goodarzi H, Garcia MS, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 2013; 44:121.</a></li><li><a class="nounderline abstract_t">Amerio P, Amoruso G, Bardazzi F, et al. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. J Dermatolog Treat 2013; 24:305.</a></li><li><a class="nounderline abstract_t">Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.</a></li><li><a class="nounderline abstract_t">Aggarwal R, Manadan AM, Poliyedath A, et al. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009; 36:914.</a></li><li><a class="nounderline abstract_t">Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167:1145.</a></li><li><a class="nounderline abstract_t">Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol 2014; 171:884.</a></li><li><a class="nounderline abstract_t">Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology 2017; 6:e152.</a></li><li><a class="nounderline abstract_t">Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418.</a></li><li><a class="nounderline abstract_t">Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019; 21:111.</a></li><li><a class="nounderline abstract_t">van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75:83.</a></li><li><a class="nounderline abstract_t">Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol 2019; 33:333.</a></li><li><a class="nounderline abstract_t">Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol 2020; 82:352.</a></li><li><a class="nounderline abstract_t">Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2019; 180:1039.</a></li><li><a class="nounderline abstract_t">Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol 2018; 179:615.</a></li><li><a class="nounderline abstract_t">Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392:650.</a></li></ol></div><div id="topicVersionRevision">Topic 15279 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250239" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Consensus guidelines for the management of plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19527820" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811848" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727462" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610329" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HIV-associated psoriasis: pathogenesis, clinical features, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646777" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485527" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14708680" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology of hepatitis B in Europe and worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Natural history of chronic hepatitis B REVEALed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811850" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/87091" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Liver biopsy in PUVA-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3950113" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7451691" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8308218" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229152" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Toxic hepatitis after PUVA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10570561" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/92158" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Liver injury following administration of 8-methoxypsoralen during PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21901356" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173926" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306066" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229464" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1119817" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Letter: Complications during methotrexate therapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19998529" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A review of acitretin for the treatment of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459140" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acitretin in psoriasis: an overview of adverse effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10495381" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of acitretin on the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2147707" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2130300" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382464" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20561122" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety of anti-tumour necrosis factor-αagents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22985451" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746170" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188392" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448284" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880218" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28495497" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077677" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of anti-tumor necrosis factor-αtherapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089354" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-αinhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945310" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121260" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28960490" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety of secukinumab in hepatitis B virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28960490" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety of secukinumab in hepatitis B virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22671985" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28449227" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Apremilast for a psoriasis patient with HIV and hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578868" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14672695" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Specific inhibition of hepatitis C virus replication by cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040279" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068808" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of cyclosporin in a patient with hepatitis C and pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21070334" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of psoriasis in patients with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22783348" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17441954" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791697" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690185" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713482" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Etanercept therapy in two patients with psoriasis and concomitant hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20673536" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful treatment of hand and foot psoriasis with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389194" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21375517" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tumour necrosis factor-αantagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924392" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305904" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of psoriasis with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543290" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956650" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27605880" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Management of psoriasis patients with hepatitis B or hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26481193" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909423" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Zidovudine improves psoriasis in human immunodeficiency virus-positive males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203394" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070027" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338845" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2913083" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2041889" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922012" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16911402" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Testing for HIV prior to methotrexate administration. Is it an obligatory procedure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335741" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The safety of UVB phototherapy in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2186752" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2120288" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2795711" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555008" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9267752" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of PUVA therapy on HIV viremia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9197824" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8034807" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The use of methotrexate for treatment of psoriasis in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28416342" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347382" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Use of cyclosporin for psoriasis in HIV-positive patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308575" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19932926" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321777" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Use of infliximab to treat psoriatic arthritis in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099388" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079191" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395596" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040859" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787206" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Ustekinumab for the treatment of HIV psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759856" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26184440" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934089" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact of screening for latent TB prior to initiation of anti-TNF therapy in North America and Europe</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22311162" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22208431" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614731" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332623" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22803615" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24863903" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28868144" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28057361" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31046809" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27180926" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30198588" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31175909" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30485400" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29742274" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097359" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
